Table 2.
Patient perception of osteoarthritis symptoms and overall health status as assessed by the PGA or POHA, after treatment with diclofenac sodium topical solution, vehicle control, or placebo
| Reference | Variable | TDiclo | Vehicle control | P valuea | Placebo control | P valueb |
|---|---|---|---|---|---|---|
| Bookman et al23 | PGA (sum of scores at weeks 1, 2, 3, and 4) | 6.7 | 7.8 | 0.039 | 7.8 | 0.025 |
| Roth and Shainhouse24 | PGA (change from baseline) | −1.3 (42.2%) | −0.9 (30.4%) | 0.003 | – | – |
| Baer et al25 | PGA (change from baseline) | −1.3 (41.9%) | −0.7 (21.9%) | 0.0001 | – | – |
| Simon et al26 | PGA (change from baseline) | −1.36 (43.6%) | −1.07 (34.2%) | 0.018 | −1.01 (33.2%) | 0.016 |
| POHA (change from baseline) | −0.95 (40.6%) | −0.65 (28.3%) | 0.016 | −0.37 (16.7%) | <0.0001 |
a
Notes: TDiclo vs vehicle control;
b
TDiclo vs placebo. PGA and POHA were assessed on a scale of 0 to 4. Values shown indicate change from baseline (% improvement).
Abbreviations: OA, osteoarthritis; PGA, Patient Global Assessment; POHA, Patient Overall Health Assessment; TDiclo, diclofenac sodium topical solution.